Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

A medical expert warned of the side effects of the newly launched weight loss drug and advised that the drug should be taken ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Global diabetes drug Ozempic (semaglutide) has now been launched in India by Danish pharmaceutical major Novo Nordisk. In an ...

Novo Nordisk launches Ozempic in India, outlining prices, doses, and its bid to capture rising diabetes and weight-loss ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The ...

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Investigation ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans ...